Enveda Biosciences
Category: AI in Biotech / Drug Discovery
AI-driven natural-product drug discovery company that decodes nature's chemistry to find and develop novel small-molecule medicines. Enveda Biosciences was founded in 2019. The company is led by Viswa Colluru, PhD. Based in Boulder, Colorado, USA. Team size: 101-500. Total funding raised: $845M. Latest round: Series E. Key investors include Catalio Capital Management, Lux Capital, Sanofi, Premji Invest, True Ventures, FPV Ventures, Kinnevik, Wireframe Ventures, Baillie Gifford, Dimension Capital Management, IA Ventures, Socium Ventures.
- Founded
- 2019
- Headquarters
- Boulder, Colorado, USA
- Team size
- 101-500
- Total funding
- $845M
Value proposition
Uses an AI/ML platform (PRISM) combined with mass spectrometry to rapidly identify and characterize bioactive molecules from natural sources, turning them into drug candidates roughly 4x faster than traditional discovery methods.
Products and solutions
PRISM AI discovery platform, proprietary natural-product chemical database, internal drug pipeline including candidates in atopic dermatitis and metabolic/obesity disease with early positive clinical readouts in 2026.
Unique value
Combines mass-spectrometry-based structural elucidation with generative AI to unlock 99.9% of previously uncharacterized natural chemical diversity for drug discovery, compressing discovery timelines significantly versus industry average.
Target customer
Pharmaceutical partners and its own internal clinical pipeline (immune, metabolic/obesity, dermatology indications); B2B pharma partnerships plus proprietary drug development.
Industries served
Biotech / Pharmaceuticals, Drug Discovery, Immunology, Metabolic Disease
Technology advantage
PRISM platform integrates large-scale natural-product chemistry data with generative/predictive AI models to rank and prioritize molecules; large proprietary spectral/structural dataset built from natural sources.
How they differentiate
Focus specifically on natural-product chemistry (vs. purely synthetic/de novo AI design used by competitors), leveraging evolutionary chemical diversity as a discovery substrate combined with proprietary mass-spec + AI pipeline.
Main competitors
Recursion Pharmaceuticals, Isomorphic Laboratories, Generate Biomedicines
Key partnerships
Sanofi (strategic investment + collaboration tied to Series C, $20M), Colorado BioScience Association, India R&D subsidiary (Enveda Therapeutics India Pvt Ltd, Hyderabad).
Major milestones
2019: Founded, 2020: $5M Seed, 2021: $51M Series A (Lux Capital), 2023: Series B, Feb 2025: $150M Series C with Sanofi investment, Sept 2025: $150M Series D, reached unicorn status, first patient enrolled in lead program, Sept 2026: $311M Series E led by Catalio Capital Management at $2B valuation, positive early clinical readouts.
Growth metrics
Reached unicorn status with Series D (Sept 2025); valuation doubled to ~$2B with Series E (Sept 2026); two positive early clinical readouts in 2026 (atopic dermatitis, metabolic health); employee headcount grew to ~350-500 as of 2026.
Market positioning
Clinical-stage AI-native biotech positioning itself among the best-funded AI drug discovery unicorns, moving from platform/discovery stage into late-stage clinical trials ahead of a potential IPO.
Geographic focus
United States (primary), with R&D operations in India; competing globally against AI drug discovery leaders in US/UK.
About Viswa Colluru, PhD
Ex-Recursion Pharmaceuticals (early team, immuno-oncology background); PhD in computational chemistry/biology. Founded Enveda in 2019.
Latest news about Enveda Biosciences
More AI in Biotech / Drug Discovery companies
Official website: https://enveda.com